Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets

Gilead Sciences has announced plans to acquire Ouro Medicines for approximately $2.18 billion, with intentions to develop the acquired assets in collaboration with Galapagos. This strategic move is expected to enhance Gilead's portfolio in the biotechnology sector.

The acquisition signifies Gilead's commitment to expanding its research capabilities and product offerings, potentially leading to innovative treatments and strengthening its position in the competitive pharmaceutical market.